HUP9904545A2 - Sibutramint és analógjait tartalmazó gyógyszerkészítmény húgysavszint csökkentésére - Google Patents
Sibutramint és analógjait tartalmazó gyógyszerkészítmény húgysavszint csökkentéséreInfo
- Publication number
- HUP9904545A2 HUP9904545A2 HU9904545A HUP9904545A HUP9904545A2 HU P9904545 A2 HUP9904545 A2 HU P9904545A2 HU 9904545 A HU9904545 A HU 9904545A HU P9904545 A HUP9904545 A HU P9904545A HU P9904545 A2 HUP9904545 A2 HU P9904545A2
- Authority
- HU
- Hungary
- Prior art keywords
- uric acid
- analogues
- lowering
- pharmaceutical composition
- acid containing
- Prior art date
Links
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title abstract 2
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title abstract 2
- 229940116269 uric acid Drugs 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 title 1
- 229960004425 sibutramine Drugs 0.000 title 1
- KFNNPQDSPLWLCX-UHFFFAOYSA-N 1-[1-(4-chlorophenyl)cyclobutyl]-n,n,3-trimethylbutan-1-amine;hydron;chloride;hydrate Chemical compound O.Cl.C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 KFNNPQDSPLWLCX-UHFFFAOYSA-N 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 abstract 1
- 201000005569 Gout Diseases 0.000 abstract 1
- 201000001431 Hyperuricemia Diseases 0.000 abstract 1
- 208000029078 coronary artery disease Diseases 0.000 abstract 1
- 239000003085 diluting agent Substances 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 230000002265 prevention Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229960005303 sibutramine hydrochloride monohydrate Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
Landscapes
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Obesity (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Materials For Medical Uses (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Crystals, And After-Treatments Of Crystals (AREA)
Abstract
A találmány tárgya eljárás a húgysavszint csökkentésére, ezzelösszefüggésben a köszvény, hyperurikaemia vagy szívkoszorúér-megbetegedés megelőzésére az ilyen állapotok kifejlődése fokozottveszélyének kitett személyeknél. A találmány szerint az arra szorulószemélynek egy általános képletű vegyület - ahol R1 és R2 jelentéseegymástól függetlenül hidrogénatom vagy metilcsoport - vagy valamelyenantiomerjének vagy gyógyászatilag elfogadható sójának terápiásanhatásos mennyiségét adják be, gyógyászatilag elfogadható hígítószerrelvagy hordozóval kombinálva. Az (I) általános képletű vegyületek közüla legelőnyösebb az N,N-dimetil-1-[1-(4-klór-fenil)-ciklobutil]-3-metil-butil-amin-hidroklorid-monohidrát (sibutramin-hidroklorid-monohidrát). Ó
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB9619962.5A GB9619962D0 (en) | 1996-09-25 | 1996-09-25 | Medical treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP9904545A2 true HUP9904545A2 (hu) | 2000-11-28 |
| HUP9904545A3 HUP9904545A3 (en) | 2000-12-28 |
Family
ID=10800448
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9904545A HUP9904545A3 (en) | 1996-09-25 | 1997-09-15 | Pharmaceutical composition for lowering the uric acid containing sibutramine and analogues |
Country Status (26)
| Country | Link |
|---|---|
| US (1) | US6162831A (hu) |
| EP (1) | EP1007023B1 (hu) |
| JP (1) | JP2001501608A (hu) |
| KR (1) | KR20000048568A (hu) |
| CN (1) | CN1231604A (hu) |
| AT (1) | ATE239460T1 (hu) |
| AU (1) | AU722129B2 (hu) |
| BG (1) | BG103278A (hu) |
| BR (1) | BR9711414A (hu) |
| CA (1) | CA2266438A1 (hu) |
| DE (1) | DE69721838T2 (hu) |
| DK (1) | DK1007023T3 (hu) |
| ES (1) | ES2199374T3 (hu) |
| GB (1) | GB9619962D0 (hu) |
| HR (1) | HRP970519A2 (hu) |
| HU (1) | HUP9904545A3 (hu) |
| IL (1) | IL128851A (hu) |
| NO (1) | NO991425L (hu) |
| NZ (1) | NZ334668A (hu) |
| PL (1) | PL332423A1 (hu) |
| PT (1) | PT1007023E (hu) |
| SK (1) | SK32199A3 (hu) |
| TR (1) | TR199900649T2 (hu) |
| TW (1) | TW415842B (hu) |
| WO (1) | WO1998013033A1 (hu) |
| ZA (1) | ZA978573B (hu) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6331571B1 (en) | 1998-08-24 | 2001-12-18 | Sepracor, Inc. | Methods of treating and preventing attention deficit disorders |
| US6476078B2 (en) | 1999-08-11 | 2002-11-05 | Sepracor, Inc. | Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction |
| US6339106B1 (en) | 1999-08-11 | 2002-01-15 | Sepracor, Inc. | Methods and compositions for the treatment and prevention of sexual dysfunction |
| US6974838B2 (en) | 1998-08-24 | 2005-12-13 | Sepracor Inc. | Methods of treating or preventing pain using sibutramine metabolites |
| WO2000056306A1 (en) * | 1999-03-19 | 2000-09-28 | Knoll Gmbh | Treatment of osteoarthritis |
| US6552087B1 (en) | 1999-03-19 | 2003-04-22 | Abbott Gmbh & Co. Kg | Therapeutic agent comprising (+)-sibutramine |
| US6399826B1 (en) | 1999-08-11 | 2002-06-04 | Sepracor Inc. | Salts of sibutramine metabolites, methods of making sibutramine metabolites and intermediates useful in the same, and methods of treating pain |
| US6610887B2 (en) | 2001-04-13 | 2003-08-26 | Sepracor Inc. | Methods of preparing didesmethylsibutramine and other sibutramine derivatives |
| US9655932B2 (en) * | 2002-03-13 | 2017-05-23 | Kibow Biotech, Inc. | Composition and method for preventing or treating gout or hyperuricemia |
| US11103542B2 (en) | 2002-03-13 | 2021-08-31 | Kibow Biotech, Inc. | Composition and method for maintaining healthy kidney function |
| PL375032A1 (en) * | 2002-10-05 | 2005-11-14 | Hanmi Pharm.Co, Ltd. | Pharmaceutical composition comprising crystalline sibutramine methanesulfonate hemihydrate |
| US20050131074A1 (en) * | 2003-08-04 | 2005-06-16 | Beckman Kristen M. | Methods for treating metabolic syndrome |
| US8557831B2 (en) * | 2004-07-21 | 2013-10-15 | University Of Florida Research Foundation, Inc. | Compositions and methods for treatment and prevention of insulin resistance |
| KR100627687B1 (ko) * | 2005-04-20 | 2006-09-25 | 주식회사 씨티씨바이오 | 시부트라민 유리염기 함유 조성물 및 이의 제조방법 |
| KR20080046601A (ko) * | 2006-11-22 | 2008-05-27 | 에스케이케미칼주식회사 | 보관안정성이 우수한 시부트라민 함유 포접복합체 |
| WO2018125735A1 (en) | 2016-12-29 | 2018-07-05 | Kibow Biotech, Inc. | Composition and method for maintaining healthy kidney function |
| WO2020093069A1 (en) * | 2018-11-02 | 2020-05-07 | Ampersand Biopharmaceuticals, Inc. | Management of risk of cation overload and electrolyte imbalance with topically applied buffers |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IE52768B1 (en) * | 1981-04-06 | 1988-02-17 | Boots Co Ltd | 1-arylcyclobutylalkylamine compounds useful as therapeutic agents |
| GB8531071D0 (en) * | 1985-12-17 | 1986-01-29 | Boots Co Plc | Therapeutic compound |
| GB8704777D0 (en) * | 1987-02-28 | 1987-04-01 | Boots Co Plc | Medical treatment |
| JP2675573B2 (ja) * | 1988-03-31 | 1997-11-12 | 科研製薬株式会社 | 脳機能改善剤 |
| IE61928B1 (en) * | 1988-11-29 | 1994-11-30 | Boots Co Plc | Treatment of obesity |
| JPH08500093A (ja) * | 1992-06-23 | 1996-01-09 | セプラコア インコーポレーテッド | 光学的に純粋な（−）シブトラミンを用いるうつ病およびその他の障害を治療する方法ならびに組成物 |
| WO1994000047A1 (en) * | 1992-06-23 | 1994-01-06 | Sepracor Inc. | Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine |
| US5459164A (en) * | 1994-02-03 | 1995-10-17 | Boots Pharmaceuticals, Inc. | Medical treatment |
-
1996
- 1996-09-25 GB GBGB9619962.5A patent/GB9619962D0/en active Pending
-
1997
- 1997-09-15 PT PT97942030T patent/PT1007023E/pt unknown
- 1997-09-15 ES ES97942030T patent/ES2199374T3/es not_active Expired - Lifetime
- 1997-09-15 IL IL12885197A patent/IL128851A/xx not_active IP Right Cessation
- 1997-09-15 AT AT97942030T patent/ATE239460T1/de not_active IP Right Cessation
- 1997-09-15 DK DK97942030T patent/DK1007023T3/da active
- 1997-09-15 TR TR1999/00649T patent/TR199900649T2/xx unknown
- 1997-09-15 EP EP97942030A patent/EP1007023B1/en not_active Expired - Lifetime
- 1997-09-15 HU HU9904545A patent/HUP9904545A3/hu unknown
- 1997-09-15 NZ NZ334668A patent/NZ334668A/xx unknown
- 1997-09-15 BR BR9711414-6A patent/BR9711414A/pt not_active Application Discontinuation
- 1997-09-15 CA CA002266438A patent/CA2266438A1/en not_active Abandoned
- 1997-09-15 JP JP10515217A patent/JP2001501608A/ja active Pending
- 1997-09-15 KR KR1019990702491A patent/KR20000048568A/ko not_active Application Discontinuation
- 1997-09-15 DE DE69721838T patent/DE69721838T2/de not_active Expired - Fee Related
- 1997-09-15 SK SK321-99A patent/SK32199A3/sk unknown
- 1997-09-15 WO PCT/EP1997/005034 patent/WO1998013033A1/en not_active Application Discontinuation
- 1997-09-15 US US09/269,339 patent/US6162831A/en not_active Expired - Fee Related
- 1997-09-15 CN CN97198232A patent/CN1231604A/zh active Pending
- 1997-09-15 PL PL97332423A patent/PL332423A1/xx unknown
- 1997-09-15 AU AU43851/97A patent/AU722129B2/en not_active Ceased
- 1997-09-25 HR HR9619962.5A patent/HRP970519A2/hr not_active Application Discontinuation
- 1997-09-25 TW TW086113992A patent/TW415842B/zh not_active IP Right Cessation
- 1997-09-25 ZA ZA978573A patent/ZA978573B/xx unknown
-
1999
- 1999-03-24 NO NO991425A patent/NO991425L/no unknown
- 1999-03-24 BG BG103278A patent/BG103278A/xx unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP1007023B1 (en) | 2003-05-07 |
| ES2199374T3 (es) | 2004-02-16 |
| IL128851A0 (en) | 2000-01-31 |
| BG103278A (en) | 2000-01-31 |
| TR199900649T2 (xx) | 1999-07-21 |
| CA2266438A1 (en) | 1998-04-02 |
| AU722129B2 (en) | 2000-07-20 |
| NO991425D0 (no) | 1999-03-24 |
| SK32199A3 (en) | 1999-12-10 |
| PT1007023E (pt) | 2003-08-29 |
| WO1998013033A1 (en) | 1998-04-02 |
| CN1231604A (zh) | 1999-10-13 |
| DE69721838D1 (de) | 2003-06-12 |
| ATE239460T1 (de) | 2003-05-15 |
| US6162831A (en) | 2000-12-19 |
| HRP970519A2 (en) | 1998-08-31 |
| TW415842B (en) | 2000-12-21 |
| NZ334668A (en) | 2000-07-28 |
| GB9619962D0 (en) | 1996-11-13 |
| PL332423A1 (en) | 1999-09-13 |
| KR20000048568A (ko) | 2000-07-25 |
| HUP9904545A3 (en) | 2000-12-28 |
| DK1007023T3 (da) | 2003-08-25 |
| BR9711414A (pt) | 2000-04-25 |
| ZA978573B (en) | 1999-03-25 |
| EP1007023A1 (en) | 2000-06-14 |
| IL128851A (en) | 2001-08-26 |
| DE69721838T2 (de) | 2004-01-22 |
| NO991425L (no) | 1999-03-24 |
| JP2001501608A (ja) | 2001-02-06 |
| AU4385197A (en) | 1998-04-17 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HUP9904545A2 (hu) | Sibutramint és analógjait tartalmazó gyógyszerkészítmény húgysavszint csökkentésére | |
| HUP9904026A2 (hu) | Sibutraminanalógok alkalmazása diabetes kifejlődésének megelőzésére | |
| DE69308395D1 (de) | Pyrazolderivate, Verfahren zu ihrer Herstellung und diese enthaltende pharmazeutische Zusammensetzungen | |
| IL112515A (en) | Pharmaceutical composition containing N,N-dimethyl-1-¬1-(4-chlorophenyl)cyclobutyl¾-3-methylbutylamine for use in the treatment of non-insulin dependent diabetes mellitus | |
| HUP0002960A2 (hu) | Aril-oxi-szulfonil-amino-hidroxámsav-származékok | |
| KR950016725A (ko) | 폐 고혈압성 질병을 억제하는 방법 | |
| US4165376A (en) | Treatment of the acute after-effects resulting from alcohol ingestion | |
| KR950704314A (ko) | 1,8-나프티리딘-2-온 유도체 및 그 사용 방법(1,8-naphthyridin-2-one derivative and use thereof) | |
| HUP0202384A2 (hu) | Szubsztituált fenoxiecetsav-származékok | |
| NO20004931L (no) | Anvendelse av dexmedetomidin til sedering pÕ intensivavdeling | |
| HUP0300615A2 (hu) | Sibutramint és orlistatot tartalmazó gyógyszerkészítmény | |
| EP1949893A3 (en) | Quinazoline derivatives useful for the treatment of peripheral arterial disease and as phosphodiesterase inhibitors | |
| HUP0104963A2 (hu) | Bőrbetegségek kezelésére szolgáló készítmények | |
| WO2000056315A8 (en) | Treatment of pain | |
| MXPA01009467A (es) | Metodo para controlar el aumento de peso asociado con farmacos terapeuticos. | |
| KR910009257A (ko) | 이펜프로딜 및 그의 유도체를 유효성분으로 하는 정신병치료제 | |
| KR950016720A (ko) | 아밀로이드 단백질의 효과를 저해하는 방법 | |
| RU99108729A (ru) | Способ лечения | |
| Ogino et al. | Nicorandil suppressed myocardial purine metabolism during exercise in patients with angina pectoris | |
| WO1996007415B1 (en) | Myocardial protection using benzothiazepinones | |
| JPH06279287A (ja) | 癌転移抑制剤 | |
| EP0600085B1 (en) | Inhibitor for blood vessel hypertrophy | |
| HUP0300368A2 (hu) | Gyógyszerkészítmény konstriktív vaszkuláris léziók következtében fellépő betegség kezelésére | |
| JP2001515858A (ja) | 逆行射精または無精液症治療用医薬を製造するためのスルホンアニリド誘導体の使用 | |
| Jasmin et al. | Inhibition of Glucose-6-phosphatase Activity by Hypoglycemic 2-Benzenesulfonamido-5-alkyl-1, 3, 4-thiadiazoles |